TY - JOUR
T1 - Polycystic ovary syndrome and cardiovascular disease risk
AU - Legro, Richard S.
N1 - Funding Information:
Dr. Legro has received honoraria and consulting fees from GlaxoSmithKline, Ferring, QuatRx, HRA Pharma, Abbott, and Ortho-McNeil; lecture and editorial fees from Biosymposia, Organon, Serono, the American College of Obstetricians and Gynecologists, and The Lancet; and research funding from the National Institutes of Health, the Commonwealth of Pennsylvania, and Parke-Davis. He serves on the editorial boards of the Journal of Clinical Endocrinology and Metabolism and Endocrine Reviews, is a member of the clinical research committee of the Endocrine Society, and is an associate editor of Seminars in Reproductive Medicine.
Funding Information:
This work was supported by Public Health Service grants R01HD056510, U54-HD34449, and U10-HD38992 through the Reproductive Medicine Network; grant PA-SAP-41-000-26343 from tobacco settlement funds from the Pennsylvania Department of Health; and General Clinical Research Centers grant MO1-RR-10732 to Pennsylvania State University.
PY - 2009
Y1 - 2009
N2 - Women with polycystic ovary syndrome (PCOS), an endocrinopathy consisting of oligo-ovulation, excess androgen, and polycystic ovaries, commonly have an adverse cardiovascular risk profile. This profile is exacerbated by obesity, which is common among women with the syndrome, especially in the United States. Recent articles from cohort and case-control studies support an increased risk of cardiovascular disease events in postmenopausal women with PCOS, though the diagnosis of PCOS in menopause is problematic. Treatment of cardiovascular risk factors, including insulin resistance, lipids, and serum markers of atherosclerosis (most commonly C-reactive protein) is receiving increasing clinical focus. While weight loss with lifestyle therapy is a universal goal in obese women, the role of additional pharmaceutical treatment of metabolic risk factors such as hyperinsulinemia and dyslipidemia is uncertain.
AB - Women with polycystic ovary syndrome (PCOS), an endocrinopathy consisting of oligo-ovulation, excess androgen, and polycystic ovaries, commonly have an adverse cardiovascular risk profile. This profile is exacerbated by obesity, which is common among women with the syndrome, especially in the United States. Recent articles from cohort and case-control studies support an increased risk of cardiovascular disease events in postmenopausal women with PCOS, though the diagnosis of PCOS in menopause is problematic. Treatment of cardiovascular risk factors, including insulin resistance, lipids, and serum markers of atherosclerosis (most commonly C-reactive protein) is receiving increasing clinical focus. While weight loss with lifestyle therapy is a universal goal in obese women, the role of additional pharmaceutical treatment of metabolic risk factors such as hyperinsulinemia and dyslipidemia is uncertain.
UR - http://www.scopus.com/inward/record.url?scp=84860384553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860384553&partnerID=8YFLogxK
U2 - 10.1007/s12170-009-0011-1
DO - 10.1007/s12170-009-0011-1
M3 - Article
AN - SCOPUS:84860384553
VL - 3
SP - 65
EP - 70
JO - Current Cardiovascular Risk Reports
JF - Current Cardiovascular Risk Reports
SN - 1932-9520
IS - 1
ER -
